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Abstract
( )Reports of frequent loss of heterozygosity LOH of
markers on human chromosome 7q in malignant
myeloid disorders as well as breast, prostate, ovarian,
colon, head and neck, gastric, pancreatic, and renal cell
carcinomas suggest the presence of a tumor suppres-
( )sor gene TSG . Functional assays have demonstrated
that the introduction of an intact copy of human chro-
( )mosome 7 hchr7 can restore senescence to immortal-
ized human fibroblast cell lines having LOH of markers
within 7q31-q32 and can inhibit the tumorigenic pheno-
type of a murine squamous cell carcinoma cell line. To
facilitate the cloning of the putative TSG, we have con-
structed a high-resolution physical map of this region
of hchr7, specifically that encompassing the markers
D7S522 and D7S677 within 7q31.1-q31.2. By using a
lower resolution yeast artificial chromosome-basedmap
as a starting framework, we established complete clone
coverage of the implicated critical region in bacterial-
( )artificial chromosomes BACs and P1-derived artificial
( )chromosomes PACs . The resulting BAC/PAC-based
contig map has provided suitable clones for the sys-
tematic sequencing of the entire interval. In addition,
we have already identified 29 clusters of overlapping
( )expressed-sequence tags ESTs and 4 known genes
contained within these clones. Together, the physical
map reported here coupled with the evolving sequence
and gene maps should hasten the identification of the
putative TSG residing within this region of hchr7.
Keywords: tumor suppressor gene, human chromosome 7, physical mapping,
expressed-sequence tag, bacterial artificial chromosome.
Introduction
( )Frequent loss of heterozygosity LOH of a specific chromo-
( )somal marker s is considered an indication of a closely
( ) [ ]linked tumor suppressor gene TSG 1 . The association of
specific interstitial deletions within chromosome 7q and a
[ ]variety of human neoplasias is now well-established 2 .
Specifically, frequent LOH of markers located within
[ ]7q31.1-q31.2 has been observed in breast 3,4 , prostate
[ ] [ ] [ ] [ ]5,6 , ovarian 7,8 , colon 9 , head and neck 9 , gastric
[ ] [ ] [ ]10,11 , pancreatic 12 , and renal cell carcinomas 13 as
[ ]well as in malignant myeloid disorders 14 . This collection
of molecular cytogenetic data in conjunction with numerous
classical cytogenetics studies showing frequent deletions
and alterations within chromosome 7q in a variety of human
[ ]neoplasias 15 suggests the presence of a TSG.
The results of functional complementation studies also
indicate the presence of a TSG on chromosome 7q. Specifi-
cally, microcell-mediated chromosome-transfer studies have
shown that the introduction of an intact copy of human
( )chromosome 7 hchr7 can restore senescence to human
fibroblast cell lines known to have LOH within 7q31-q32
[ ]16 . We have shown that the introduction of a single hchr7
inhibits the tumorigenicity of a mouse squamous cell carci-
[ ]noma cell line 17 and a highly malignant human prostate
( ) (carcinoma cell line PC3 J.C.Z. and E.D.G., unpublished
)data . Furthermore, reversion of the resulting suppressed
cell lines back to a more tumorigenic state is associated
with deletions in 7q31.1-q31.2. Finally, Matsuda and
coworkers demonstrated that hchr7 can suppress tumori-
[ ]genicity of a choriocarcinoma cell line 18 . Taken together,
these findings strongly suggest that a TSG resides in hu-
man chromosome 7q31.1-q31.2.
To accelerate the isolation of this putative TSG, we
sought to construct a highly detailed physical map of this
well-defined region of hchr7. As part of the ongoing Human
Genome Project, our laboratory has been heavily engaged
in the mapping and sequencing of hchr7; for example, we
recently reported the completion of a yeast artificial chromo-
( )some YAC -based physical map of the entire chromosome
[ ]19 . The latter provides information about the relative posi-
( )tions of numerous sequence-tagged sites STSs across
hchr7. These mapped STSs provide a powerful framework
for assembling more detailed maps, such as higher-resolu-
tion physical maps consisting of bacterial artificial chromo-
( ) [ ]somes BACs 20,21 and P1-derived artificial chromo-
( ) [ ]somes PACs 22 .
Abbreviations: BAC, bacterial artificial chromosome; EST, expressed-sequence
tag; hchr, human chromosome; LOH, loss of heterozygosity; PAC, P1-derived
artificial chromosome; STS, sequence-tagged site; TSG, tumor suppressor gene;
YAC, yeast artificial chromosome.
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The availability of complete BAC/PAC coverage of the
hchr7 region believed to harbor the TSG would be valuable
for several purposes. First, the use of large-insert bacterial
clones would allow the construction of a highly accurate
physical map of the region, providing both ready access to
the DNA in an experimentally convenient form and the
ability to position sequences of interest at high resolution.
The latter effort could include the more precise localization
( )of the numerous expressed-sequence tags ESTs being
[ ]coarsely mapped throughout the human genome 23,24
( )http://www.ncbi.nlm.nih.gov/genemap . Specifically, poly-
( )merase chain reaction PCR assays can be developed for
( )ESTs or EST clusters mapping to the general vicinity of
7q31-q32 and used to test the available BACs/PACs,
thereby establishing whether the corresponding sequences
truly reside within the critical region of interest. Second, a
properly constructed BAC/PAC contig map can be used for
the systematic sequencing of the region. The resulting se-
quence data would provide information about additional
ESTs and insight as to the position and structure of the
corresponding genes. Finally, the available mapped BACs/
PACs can be harnessed with appropriate mammalian se-
[ ]lectable markers 25 and introduced into appropriate cell
lines for functional complementation studies to test for the
presence of the TSG.
Here we report the construction of a complete BAC/
PAC-based physical map of the hchr7 critical region harbor-
ing the putative TSG. Information about the rapidly evolving
sequence and gene map of the region is also provided.
Together, these studies are facilitating the identification and
evaluation of candidates for this TSG.
Materials and Methods
Polymerase Chain Reaction
PCR assays were performed in a total volume of 10 ml
and contained either 0.1 mg of genomic DNA, purified by a
[ ]standard phenol-chloroform extraction protocol 26 , or BAC
[ ]DNA, prepared by a modified alkaline lysis protocol 25 , 60
(pmol of each primer, 200 mmol/L dNTPs dATP, dCTP,
) ( [ ]dGTP, dTTP , 1X buffer 10 mmol/L Tris-HCl pH 8.3 , 1.5
)mmol/L MgCl , 50 mmol/L KCl, and 0.001% gelatin , and2
(0.5 units of AmpliTaq polymerase. The latter three compo-
)nents were purchased from Perkin-Elmer, Norwalk, CT .
Thermal cycling consisted of 35 cycles of 20 seconds at
948C, 30 seconds at 558C, and 15 seconds at 728C in a
( )9600 Thermocycler Perkin-Elmer . PCR products were
(electrophoresed in 2.5% MetaPhor FMC Bioproducts,
) 2 [Rockland, ME agarose gels at 3.5 V/cm in TBE buffer 89
mmol/L Tris-borate, 89 mmol/L boric acid, 2 mmol/L eth-
( )]ylenetetraamineacetic acid pH 7.5 containing 0.5 mg/ml
ethidium bromide and imaged with UV light.
LOH Determination
LOH analyses of tumor DNA samples were performed as
[ ]previously described 4,5,7,9 . LOH was defined as the
complete loss or a greater than 70% reduction in the signal
intensity for 1 allele.
BAC/PAC Isolation
(BACs were isolated from the Research Genetics http://
) (www.resgen.com and Genome Systems http://
)www.genomesystems.com human BAC libraries by PCR
screening according to the suppliers’ instructions. PACs
(were isolated from the Roswell Park Cancer Institute Buf-
) ( )falo, NY human PAC library http://bacpac.med.buffalo.edu
by hybridization-based screening. Following isolation, clones
were colony purified and tested for the presence of se-
( )quence-tagged sites STSs by PCR.
Generation of BAC Insert-End Sequences
Insert-end sequences from selected BACs were obtained
as follows. BAC DNA was purified using an Autogen 740
(Automated Nucleic Acid System Integrated Separation
Systems, Princeton, NJ, and concentrated to 200 ng/ml
( )using a Microcon-100 column Amicon, Bedford, MA . Fluo-
rescent DNA sequencing was done with -40M13F and
( )
-28M13R primers Clontech, Palo Alto, CA and BigDye
( )terminators Perkin-Elmer . The 20-ml sequencing reaction
( )contained 11ml of purified BAC DNA at 200 ng/ml , 1ml of
( )primer at 10 mM , and 8 ml of BigDye reaction mixture.
Thermal cycling was performed as suggested by the manu-
facturer. The products from each reaction were then purified
(on a Centrisep column Princeton Separations, Adelphia,
)NJ , dried, resuspended in 2 ml of loading buffer, and
analyzed on an automated fluorescent sequencing instru-
( )ment Applied Biosystems 377, Norwalk, CT . Repetitive
elements in the resulting sequences were then masked
(using the program RepeatMasker http:// ftp.genome.
)washington.edu/cgi-bin/RepeatMasker , and primers suit-
(able for PCR were designed with MacVector software Ox-
)ford Molecular, Madison, WI .
Detection of Matching ESTs in Genomic Sequence Data
Prefinished and finished BAC/PAC sequences were im-
ported from the Washington University Genome Sequenc-
(ing Center ftp:// www.genome.wustl.edu / pub / gsc1 /
)sequence/st.louis/human . After the masking of repetitive
[ ]sequences with RepeatMasker, PowerBLAST 27 analysis
( )was done, and the results retrieved in hypertext HTML
format. The resulting reports were manually browsed to
identify matching ESTs as well as known genes.
Results
[ ]Previous studies 4,5,7,9 indicated that the critical region
on hchr7 harboring the putative TSG was defined by the
( )flanking markers D7S522 and D7S677 Figure 1 . In an
effort to refine this interval, we analyzed a representative
(set of tumors from a variety of epithelial sources breast,
)prostate, ovary, and colon that we had previously charac-
[ ]terized for LOH in this region 4,5,7,9 . Specifically, 14
specimens with a small area of LOH comprising the mark-
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Figure 1. Clone-based physical map of the region of human chromosome 7q31.1-q31.2 containing the putative TSG
( ) ( )oriented with the centromere leftward and the 7q telomere rightward . A The deduced positions of the indicated STSs
( )are depicted STS names begin with the prefix sWSS . Relevant information about the STSs and their corresponding PCR
( )assays is available in GenBank see http://www.ncbi.nlm.nih.gov/dbSTS . STSs are depicted in an equidistant fashion
(from one another. Listed above many of the STSs are the corresponding D7S numbers in the case of genetic markers;
) ( )shown in blue and GenBank accession numbers in the case of genes and ESTs; shown in green . For the genes/ESTs,
(the indicated GenBank accession number corresponds to the sequence from which the STS was derived. See Table 2 for
)additional GenBank records corresponding to the genes and ESTs. In the case of a known gene, the STS was developed
( )from the sequence of the first exon with the name of the gene provided in parenthesis . An additional STS was also
( ) ( )developed from the promoter region of MET ‘METP’ . B The relative positions of BACs and PACs, indicated as
horizontal lines, are indicated. Clones are named starting with the following prefixes, which reflect their library of origin: RG
( ) ( ) (Research Genetics human BAC library , GS Genome Systems human BAC library , and DJ Roswell Park Cancer
)Institute human PAC library . A square indicates that the STS was verified in that clone by PCR testing, whereas a circle
indicates that the STS was verified by both PCR testing and identification of the STS within sequence generated from that
clone. Note that this figure depicts a representative subset of the total BACs/PACs known to map to this region, with a
[ ]larger contig constructed by restriction enzyme digest–based fingerprint analysis 28 as part of a collaborative effort with
the Washington University Genome Sequencing Center. A map of the latter contig is available as an electronic supplement
( )to this paper see http://genome.nhgri.nih.gov/CHR7/Neoplasia99 . The clones selected for sequencing by the Washing-
( ) ( )ton University Genome Sequencing Center see http://genome.wustl.edu /gsc are boxed. C A small, representative set
( [ ] )of YACs spanning the region. See Bouffard et al. 19 for additional details about the complete YAC contig map. Solid and
( )open squares indicate if the STS was present or not, respectively, in that YAC by PCR testing. D The previous and
( )refined critical regions containing the putative TSG are indicated additional details in text , with the approximate sizes
indicated as deduced from the BAC/PAC sequence data.
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Table 1. BACs/PACs Being Sequenced by the Washington University
Genome Sequencing Center.
BAC/PAC Insert Status GenBank
) †( )Size kb Accession No.
RG030h15 151 Finished AC002066
‡RG011k01 157 Prefinished AC006159
RG253b13 171 Finished AC002080
RG013n12 184 Finished AC004416
RG300c03 150 Finished AC002543
‡RG099b05 130 Prefinished AC005063
RG114a06 188 Finished AC002542
DJ0866n18 101 Finished AC003987
‡RG234b20 157 Prefinished
RG343p13 155 Finished AC002465
RG205g13 82 Finished AC003045
RG068p20 150 Finished AC000111
)Derived from sequence data.
†See http://www.ncbi.nlm.nih.gov.
‡Sequencing in progress, with preliminary data already available.
ers D7S522 and/or D7S677 were analyzed for 3 STSs
( )sWSS843, sWSS844, and sWSS850 that both map to the
[ ]region 19 and amplify polymorphic segments. One of these
STSs, sWSS850, failed to show LOH in some of the tumors,
indicating that this marker resided outside the interval of
interest. These results reduce the critical region by approxi-
( )mately 200 kb from the telomeric end Figure 1 .
[ ] (Our YAC-based STS-content map of hchr7 19 http://
)www.nhgri.nih.gov/DIR/GTB/CHR7 provided a valuable
starting point for mapping the interval containing the puta-
tive TSG. Specifically, the defined critical region resides on
[ ( )]a single YAC contig contig O sWSS23 , with a minimal set
of the YACs spanning this interval shown in Figure 1. We
assembled a complete bacterial clone-based contig map
encompassing this critical region. Specifically, positive BACs
and/or PACs were isolated for each of the 30 STSs previ-
ously localized on our YAC contig map. An additional 32
STSs corresponding to known genes and ESTs were also
mapped relative to these BACs/PACs. These included
( )several STSs sWSS4859, sWSS4864, and sWSS4872
derived from EST clusters positioned on the genome-
[ ] (wide transcript map 23,24 http://www.ncbi.nlm.nih.gov/
)genemap . Based on the resulting STS content of the clones,
two nascent BAC/PAC contigs were assembled. Two new
( )STSs sWSS4263 and sWSS4420 were then developed
from the insert-ends of clones located at the ends of the two
nascent contigs, and these were in turn used to isolate
additional clones. This process resulted in the merger of the
two smaller contigs to form the single contig shown in
Figure 1. Note that the depicted BAC/PAC contig spans
approximately 1.4 Mb and contains 62 STSs, thereby pro-
viding an average STS spacing of approximately 23 kb.
In parallel with our STS mapping efforts, the clones
(shown in Figure 1 as well as a larger set of BACs/PACs
)isolated by hybridization-based screening were analyzed at
the Washington University Genome Sequencing Center
( )http://genome.wustl.edu/gsc by a restriction enzyme di-
[ ]gest-based fingerprint strategy 28 . The resulting BAC/PAC
(contig available at http:// genome.nhgri.nih.gov / CHR7 /
)Neoplasia99 is fully consistent with that depicted in Figure
1 and serves to verify the accuracy of our assembled map.
( )A small number of BACs/PACs roughly 8-9 clones
provide a minimal tiling path across the hchr7 critical region
containing the putative TSG. Specific clones from the contig
( )have been selected Table 1 and are actively being se-
quenced at the Washington University Genome Sequencing
( )Center http://genome.wustl.edu/gsc . Preliminary analyses
of the resulting data are revealing the presence of
additional, previously unknown gene sequences. Specifi-
cally, in addition to the 3 EST clusters already localized
[ ] (on the genome-wide transcript map 23,24 http://
)www.ncbi.nlm.nih.gov/genemap , we have identified 26 ad-
ditional matching EST clusters within the sequence gener-
Table 2. Summary of ESTs and Known Genes Identified in Genomic
Sequence from the hchr7 TSG Critical Region.
) † ‡ §BAC/PAC Strand GenBank No. Source Gene Name
RG030h11 - D45516 Lung
- AA528351 Ewing sarcoma
- H03662 Placenta
X( )q R99005 3 , Liver/spleen
X( )R99779 5
( )RG253b13 q Z26936 MET Promoter
q J02958 MET
q M37520 MET H
X( )
- T70330 3 , Liver/spleen
X( )T70414 5
RG013n12 q H54792 Liver/spleen
q AA280265 Germ. B Cell
RG300c03 - N73000 Melanocyte
- R93791 Liver/spleen
- R94893 Liver/spleen
X( )q R94575 3 , Liver/spleen
X( )R94574 5
- H63276 Liver/spleen
- H38213 Liver/spleen
X( )
- R02106 3 , Liver/spleen
X( )R02219 5
- N47349 Multiple sclerosis
q U03851 ALPHACAP
RG099b05 - T62896 Liver
- R66201 Placenta
RG114a06 q H65143 Olfactory
q AA325774 Cerebellum
X( )q F02047 3 , Multiple sclerosis
X( )F05800 5
X( )q R07041 3 , Liver/spleen
X( )R07091 5
q AA522457 Prostate
X( )q AA043204 3 , Uterus
( X)AA043203 5
DJ0866n18 q N58116 Liver/spleen
X( )q W86346 3 , Liver/spleen
X( )W86345 5
RG343p13 q X07876 WNT2
RG068p20 q M28668 CFTR
)Some ESTs/genes are present in more than one clone. For simplicity,
(this is not indicated here see Figure 1 for the complete EST/gene
)content of each BAC/PAC .
† ( ) ( )Arbitrarily assigned strand containing that sequence: q sense and -
antisense.
‡ (GenBank accession numbers for ESTs and known genes see http://
)www.ncbi.nlm.nih.gov/Entrez/nucleotide.html . In some cases, two ac-
X X (cession numbers are provided, reflecting 3 and 5 sequence reads as
)indicated .
§Tissue or cell line from which the mRNA used for cDNA library con-
struction was derived.
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( )ated from this region Table 2 . The corresponding genes
represent viable candidates for the TSG.
Discussion
As an initial step toward the isolation of the putative TSG
residing within human chromosome 7q31.1-q31.2, we have
constructed a high-resolution physical map of the critical
region established by LOH studies. This interval was initially
defined by the flanking markers D7S522 and D7S677
[ ]4,5,7,9 ; however, based on analyses with additional poly-
morphic markers, we have slightly reduced the size of this
( ) (region Figure 1 . The refined critical region now flanked by
)D7S522 and sWSS850 is fully contained within a single
[ ]YAC contig 19 , with the STSs previously positioned along
this contig serving as the starting point for the development
of a bacterial clone-based physical map. Indeed, the avail-
ability of STSs mapped, on average, every 79 kb across the
[ ]region 19 greatly accelerated clone isolation and map
construction.
( )The resulting BAC/PAC contig Figure 1 provides highly
redundant coverage of the region as well as a set of clones
suitable for systematic sequencing. Of note, one of the
(areas where clone coverage is particularly poor sWSS2710
) ( )to sWSS3428 is covered by a BAC RG099b05 that is
(thought to contain a chimeric insert i.e., two segments of
)DNA that are not contiguous in the human genome . The
latter was discovered when new STSs were developed from
( )sequence generated from this clone, and some but not all
of these STSs mapped to hchr7. Interestingly, the hchr7
DNA within and flanking RG099b05 contains a notably large
amount of repetitive sequences. Such repeats may facilitate
the formation of chimeric clones by recombination-based
mechanisms. Furthermore, a common chromosomal fragile
( )site Fra7G has recently been localized to this general
[ ]region of hchr7 14,29 . These various observations–poor
clone coverage, a chimeric BAC, repeat-rich sequences,
frequent neoplasia-associated LOH for markers from this
[ ]region 2–15 , and the likely presence of a nearby fragile
site–may all be related. Of note, the recent discovery of a
( )TSG FHIT within the most prominent fragile site of the
[ ]human genome 30,31 suggests that TSGs may be located
in areas of chromosomal fragility.
The availability of well-mapped bacterial clones covering
the putative TSG critical region has catalyzed a couple of
important areas of investigation. First, the entire interval is
( )actively being sequenced see Table 1 , providing a wealth
of sequence data for use in additional studies. Our initial
analyses of this data have included both the identification of
( )matching gene and EST sequences Table 2 as well as the
prediction of genes and their corresponding structures by
( [ ] [ ]various computer programs GRAIL 32 , GeneScan 33 ;
)data not shown . To date, our evaluations of the matching
ESTs and predicted new genes have not uncovered a
particularly attractive candidate gene, although more de-
(tailed studies are ongoing e.g., generation of full-length
)cDNA sequences . In total, 4 known genes have been
( )identified Table 2 . Three of these are unlikely to be the
)TSG: 1 CFTR, the gene mutated in cystic fibrosis that
[ ] )encodes an AMP-regulated chloride channel 34 ; 2 MET,
which encodes an oncogene with a variety of known func-
[ ] )tions in tumorigenesis 35 ; and 3 WNT2, which encodes a
[ ]mitogenic factor that is up-regulated in breast cancer 36 . In
( )contrast, the fourth known gene ALPHACAP encodes the
F-actin capping protein alpha and represents a viable candi-
date. It is a member of a family of regulating proteins that
are involved in the capping of the actin filament after elon-
gation is completed. It is also known to release the actin
filament allowing cytoskeletal reorganization as a result of
[ ]mitogenic stimuli 37,38 . Interestingly, it has been sug-
gested that members of the actin family may play a role in
the regulation of angiogenesis by interacting with angio-
[ ]genins 38 . Based on our studies showing that the re-
pressed hybrid cell lines obtained by microcell fusion retain
[ ]the proliferation rate of the parental cell lines 17 , it seems
unlikely that the TSG encodes a cell-cycle regulator; rather,
it is more likely that the TSG product functions within a
(pathway such as cell-host interaction e.g., angiogenesis,
)matrix remodeling . The latter notion makes ALPHACAP a
good candidate for further evaluation.
A second area of investigation accelerated by the re-
ported clone-based physical map involves the use of func-
tional complementation assays with the characterized BACs
/PACs. Specifically, clones of interest are being retrofitted
[ ]with suitable mammalian selectable markers 25,39 and
introduced into tumorigenic cell lines. Repression of tumor
formation with specific BACs/PACs may provide additional
clues about the location and functionality of the putative
TSG.
In summary, the studies reported here illustrate how the
fruits of the Human Genome Project can be used to acceler-
ate research in human oncology. Specifically, an approxi-
mately 1-Mb segment of hchr7 presumed to harbor an
important TSG has been isolated in bacterial clones, allow-
ing the sequencing of the entire interval to commence and
providing valuable informational and experimental tools that
will facilitate the study of genes residing in the region.
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